Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 4/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | RECQL | P46063 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | TLR3 | O15455 | 1/20 | 0.45 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | HASPIN | Q8TF76 | 2/20 | 0.42 |
| ▸ | DYRK2 | Q92630 | 2/20 | 0.42 |
| ▸ | HTR1A | P08908 | 2/20 | 0.42 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2312023 | 1.00 | KIT (0.73) | KITKDM4ENPSR1RAB9APOLB | |
| SCHEMBL2314192 | 0.96 | KIT (0.76) | KITKDM4ENPSR1RAB9APOLB | |
| SCHEMBL12387161 | 0.88 | KIT (0.66) | KITKDM4ENPSR1RAB9APOLB | |
| SCHEMBL2311284 | 0.86 | KIT (0.76) | KITKDM4ENPSR1RAB9APOLB | |
| SCHEMBL3250585 | 0.85 | KIT (0.67) | KITKDM4ENPSR1RAB9APOLB | |
| Iodide SCHEMBL2313371 | 0.85 | KIT (0.67) | KITKDM4ENPSR1RAB9APOLB | |
| SCHEMBL2317073 | 0.85 | KIT (0.78) | KITKDM4ENPSR1RAB9APOLB | |
| SCHEMBL2309766 | 0.85 | KIT (1.00) | KITKDM4ENPSR1RAB9APOLB | |
| Iodide SCHEMBL5363520 | 0.83 | KIT (0.64) | KITKDM4ENPSR1RAB9APOLB | |
| SCHEMBL12387158 | 0.82 | KIT (0.70) | KITKDM4ENPSR1RAB9APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070054905-A1 | Use of indole-derived compounds for the preparation of a medicament that can be used to treat diseases related to the splicing process | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2007-03-08 | — | — | US | claimed |
| EP-1663219-A2 | USE OF INDOLE-DERIVED COMPOUNDS FOR THE PREPARATION OF A MEDICAMENT THAT CAN BE USED TO TREAT DISEASES RELATED TO THE SPLICING PROCESS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2006-06-07 | — | — | EP | claimed |
| WO-2005023255-A2 | USE OF INDOLE-DERIVED COMPOUNDS FOR THE PREPARATION OF A MEDICAMENT THAT CAN BE USED TO TREAT DISEASES RELATED TO THE SPLICING PROCESS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2005-03-17 | — | — | WO | claimed |
| US-7989467-B2 | Use of indole-derived compounds for the preparation of a medicament that can be used to treat diseases related to the splicing process | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2011-08-02 | — | — | US | disclosed |
| US-7989467-B2 | Use of indole-derived compounds for the preparation of a medicament that can be used to treat diseases related to the splicing process | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2011-08-02 | — | — | US | disclosed |
| US-7989467-B2 | Use of indole-derived compounds for the preparation of a medicament that can be used to treat diseases related to the splicing process | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2011-08-02 | — | — | US | disclosed |
| EP-1663219-B1 | USE OF INDOLE-DERIVED COMPOUNDS FOR THE PREPARATION OF A MEDICAMENT THAT CAN BE USED TO TREAT DISEASES RELATED TO THE SPLICING PROCESS | CENTRE NAT RECH SCIENT (FR) | 2010-05-12 | — | — | EP | disclosed |
| US-20070054905-A1 | Use of indole-derived compounds for the preparation of a medicament that can be used to treat diseases related to the splicing process | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2007-03-08 | — | — | US | disclosed |
| US-20070054905-A1 | Use of indole-derived compounds for the preparation of a medicament that can be used to treat diseases related to the splicing process | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2007-03-08 | — | — | US | disclosed |
| US-20070054905-A1 | Use of indole-derived compounds for the preparation of a medicament that can be used to treat diseases related to the splicing process | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2007-03-08 | — | — | US | disclosed |
| EP-1663219-A2 | USE OF INDOLE-DERIVED COMPOUNDS FOR THE PREPARATION OF A MEDICAMENT THAT CAN BE USED TO TREAT DISEASES RELATED TO THE SPLICING PROCESS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005023255-A2 | USE OF INDOLE-DERIVED COMPOUNDS FOR THE PREPARATION OF A MEDICAMENT THAT CAN BE USED TO TREAT DISEASES RELATED TO THE SPLICING PROCESS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2005-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054905-A1 | Use of indole-derived compounds for the preparation of a medicament that can be used to treat diseases related to the splicing process | RBM17, BRCA1, SMN1; SMN2 | KIT 2116/4885KDM4E 2967/4885NPSR1 3930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.